Local News

• Long-term Titan study evaluates Prezista(R)/ritonavir vs. lopinavir/ritonavir  Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir) /ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naïve, treatment-experienced HIV-1 infected adults.
  Johnson & Johnson November 18, 2008  
• FDA extends METOZOLV(TM) ODT review date  Salix announced that the FDA has informed Wilmington Pharmaceuticals that the Prescription Drug User Fee Act action date for the New Drug Application (NDA) for METOZOLV(TM) Orally Disintegrating Tablets has been extended three months to provide time for a full review of the submission.
  Salix Pharmaceuticals, Ltd. November 18, 2008  
• Salix announces issuance of U.S. patent for rifaximin  Salix Pharmaceuticals announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,452,857. U.S. Patent No. 7,452,857 provides protection relating to rifaximin for treating irritable bowel syndrome (IBS) caused by small intestinal bacterial overgrowth.
  Salix Pharmaceuticals, Ltd. November 18, 2008  
• Magnetically steered irrigated tip cardiac catheter now available in EU  Patients in the European Union (EU) with Atrial Fibrillation and other arrhythmias, also known as irregular heart rhythms, may now benefit from treatment with an innovative state-of-the art catheter.
  Johnson & Johnson November 18, 2008  
• Monsanto announces 2008 preliminary corn yield data  While the U.S. harvest season is tracking slightly behind the national historic average, preliminary yield results reveal that corn seed products offered by Monsanto's DEKALB and American Seeds (ASI) brands are delivering opportunities for greater productivity and profitability.
  Monsanto Company November 18, 2008  
• ImClone Systems announces clearance of tender offer by German Federal Cartel Office  ImClone Systems announced that on Monday, November 17, 2008, the German Federal Cartel Office granted clearance for the acquisition of all of ImClone's common stock at a price of $70.00 per share by Alaska Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly and Company.
  ImClone Systems Incorporated November 17, 2008  
• Tyson Foods announces quarterly dividend  The Board of Directors of Tyson Foods, at a meeting on November 14, 2008, declared the quarterly dividend of $.04 per share on Class A common stock and $.036 per share on Class B common stock, payable on March 15, 2009 to shareholders of record at the close of business on March 1, 2009.
  Tyson Foods, Inc. November 17, 2008  
• Genzyme and the International Center for Genetic Engineering and Biotechnology collaborate  Genzyme and the International Center for Genetic Engineering and Biotechnology (ICGEB), a not-for-profit research and development (R&D) organization, announced a new research collaboration to advance treatments for neglected diseases.
  Genzyme Corporation November 17, 2008  
• Myozyme produced at the 2000 L bioreactor scale to receive accelerated approval  Genzyme announced that the FDA plans an Accelerated Approval for Myozyme(R) (alglucosidase alfa) produced at the 2000 L bioreactor scale for the treatment of Late Onset Pompe disease.
  Genzyme Corporation November 17, 2008  
• Lilly licenses U.S. rights for tadalafil PAH indication to United Therapeutics  Eli Lilly and Company and United Therapeutics announced that the two companies have entered into a license and a supply agreement related to the U.S. commercialization rights for the pulmonary arterial hypertension (PAH) indication of Lilly's molecule, tadalafil.
  United Therapeutics Corporation November 17, 2008  

   (next 10 articles)